🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Paul Tudor Jones’s PHAT Holdings & Trades

First Buy
Q3 2024
Duration Held
6 Quarters
Largest Add
Q3 2024
+36,383 Shares
Current Position
38,225 Shares
$424,680 Value

Paul Tudor Jones's PHAT Position Overview

Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 38,225 shares of Phathom Pharmaceuticals, Inc. (PHAT) worth $424,680, representing 0.00% of the portfolio. First purchased in 2024-Q3, this short-term holding has been held for 6 quarters.

Based on 13F filings, Paul Tudor Jones has maintained this position in PHAT for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2025, adding 34,090 shares. Largest reduction occurred in Q1 2025, reducing 34,049 shares.

Analysis based on 13F filings available since 2013 Q2

Paul Tudor Jones's Phathom Pharmaceuticals (PHAT) Holding Value Over Time

Track share changes against reported price movement

Quarterly Phathom Pharmaceuticals (PHAT) Trades by Paul Tudor Jones

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +9,671 Add 33.87% 38,225 $11.11
Q4 2025 -5,536 Reduce 16.24% 28,554 $16.59
Q3 2025 +34,090 New Buy 34,090 $11.77
Q1 2025 -34,049 Sold Out 0 $0.00
Q4 2024 -2,334 Reduce 6.42% 34,049 $8.12
Q3 2024 +36,383 New Buy 36,383 $18.08

Paul Tudor Jones's Phathom Pharmaceuticals Investment FAQs

Paul Tudor Jones first purchased Phathom Pharmaceuticals, Inc. (PHAT) in Q3 2024, acquiring 36,383 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Paul Tudor Jones has held Phathom Pharmaceuticals, Inc. (PHAT) for 6 quarters since Q3 2024.

Paul Tudor Jones's largest addition to Phathom Pharmaceuticals, Inc. (PHAT) was in Q3 2024, adding 36,383 shares worth $657,805.

According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 38,225 shares of Phathom Pharmaceuticals, Inc. (PHAT), valued at approximately $424,680.

As of the Q1 2026 filing, Phathom Pharmaceuticals, Inc. (PHAT) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.

Paul Tudor Jones's peak holding in Phathom Pharmaceuticals, Inc. (PHAT) was 38,225 shares, as reported at the end of Q1 2026.